Literature DB >> 22010515

Catching up with the catch-up: HPV vaccination coverage data for Australian women aged 18-26 years from the National HPV Vaccination Program Register.

Julia Brotherton1, Dorota Gertig, Genevieve Chappell, Lesley Rowlands, Marion Saville.   

Abstract

This report describes human papillomavirus (HPV) vaccine coverage data for Australian women 18-26 years of age, as notified to the National Human Papillomavirus Vaccination Program Register. A cross-sectional analysis was conducted of notifications to the Register of HPV vaccine doses delivered as part of the National HPV Vaccination Program, which provided free catch-up vaccination to women 18-26 years of age across Australia between 2007 and 2009. HPV vaccination coverage estimates were calculated by age, state or territory of residence and dose number, using the Australian Bureau of Statistics population estimates as the denominator. As at March 2011, approximately 4.49 million doses had been notified to the Register of females of all ages, and 1.7 million of these were for women aged 18-26 years in 2007. Vaccination coverage was highest for females aged 18 years and lowest in females aged 26 years. For the entire 18-26 years cohort, coverage was estimated at 55.2% for dose 1, 44.8% for dose 2 and 31.7% for dose 3. Notified dose 1 coverage rates by single year of age and state or territory ranged between 22% for females aged 26 years in the Northern Territory and 76% in females aged 18 years in Queensland, with dose 1 coverage highest across the age range in the Northern Territory, Queensland and South Australia. These data suggest that over half of Australian women aged 18-26 years commenced HPV vaccine courses and about one-third are fully vaccinated. Some of the differences in the coverage observed between states and territories likely reflect differing mechanisms for notifying to the Register.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22010515

Source DB:  PubMed          Journal:  Commun Dis Intell Q Rep        ISSN: 1447-4514


  9 in total

1.  Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance.

Authors:  Mari Nygård; Bo Terning Hansen; Joakim Dillner; Christian Munk; Kristján Oddsson; Laufey Tryggvadottir; Maria Hortlund; Kai-Li Liaw; Erik J Dasbach; Susanne Krüger Kjær
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

2.  Testing previous model predictions against new data on human papillomavirus vaccination program outcomes.

Authors:  Megan A Smith; Karen Canfell
Journal:  BMC Res Notes       Date:  2014-02-25

3.  Evidence of effective delivery of the human papillomavirus (HPV) vaccine through a publicly funded, school-based program: the Ontario Grade 8 HPV Vaccine Cohort Study.

Authors:  W Ting Lim; Kim Sears; Leah M Smith; Guoyuan Liu; Linda E Lévesque
Journal:  BMC Public Health       Date:  2014-10-03       Impact factor: 3.295

4.  Human papillomavirus 16/18 seroprevalence in unvaccinated women over 30 years with normal cytology and with high grade cervical abnormalities in Australia: results from an observational study.

Authors:  Louiza S Velentzis; Freddy Sitas; Dianne L O'Connell; Jessica Darlington-Brown; Sam Egger; Rohit Sinha; Emily Banks; Ian H Frazer; Karen Canfell
Journal:  BMC Infect Dis       Date:  2014-12-21       Impact factor: 3.090

5.  Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia.

Authors:  Michaela T Hall; Kate T Simms; Jie-Bin Lew; Megan A Smith; Marion Saville; Karen Canfell
Journal:  PLoS One       Date:  2018-02-14       Impact factor: 3.240

6.  Impact of catch-up human papillomavirus vaccination on cervical cancer incidence in Kenya: A mathematical modeling evaluation of HPV vaccination strategies in the context of moderate HIV prevalence.

Authors:  Gui Liu; Nelly R Mugo; Cara Bayer; Darcy White Rao; Maricianah Onono; Nyaradzo M Mgodi; Zvavahera M Chirenje; Betty W Njoroge; Nicholas Tan; Elizabeth A Bukusi; Ruanne V Barnabas
Journal:  EClinicalMedicine       Date:  2022-02-19

7.  Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.

Authors:  Dorota M Gertig; Julia M L Brotherton; Alison C Budd; Kelly Drennan; Genevieve Chappell; A Marion Saville
Journal:  BMC Med       Date:  2013-10-22       Impact factor: 8.775

8.  Transitioning from cytology-based screening to HPV-based screening at longer intervals: implications for resource use.

Authors:  Megan A Smith; Dorota Gertig; Michaela Hall; Kate Simms; Jie-Bin Lew; Michael Malloy; Marion Saville; Karen Canfell
Journal:  BMC Health Serv Res       Date:  2016-04-26       Impact factor: 2.655

9.  Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.

Authors:  Karen Canfell; Marion Saville; Michael Caruana; Val Gebski; Jessica Darlington-Brown; Julia Brotherton; Stella Heley; Philip E Castle
Journal:  BMJ Open       Date:  2018-01-26       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.